Coq10 × Antidiabetic Drugs
Mechanism
Coq10 is a weak inhibitor of CYP3A4, which decreases metabolism of CYP3A4 substrates, potentially increasing their plasma concentrations and risk of adverse effects.
Effect
Increased plasma levels of repaglinide (antidiabetic-drugs), potentially leading to toxicity or enhanced adverse effects.
Management
Monitor for increased adverse effects of repaglinide. Dose reduction may be necessary. Consider alternative supplement or consult healthcare provider.
Plain Language Summary
AI-generated · Qwen 3.6 · grounded in 2 sources · methodologyThis combination may be moderately risky because Coq10 can cause certain diabetes medications to build up in your bloodstream. This increase in medication levels may lead to a higher risk of experiencing side effects.
Source
Flockhart CYP450 Table (drug-interactions.medicine.iu.edu)
Supporting Research
Medical Disclaimer: This interaction record is for informational and educational purposes only and does not constitute medical advice. Always consult your healthcare provider or pharmacist before combining any supplement with prescription medications.